Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Retrospective Validation of the REVEAL 2.0 Risk Score With the Australian and New Zealand Pulmonary Hypertension Registry Cohort.

Anderson JJ, Lau EM, Lavender M, Benza R, Celermajer DS, Collins N, Corrigan C, Dwyer N, Feenstra J, Horrigan M, Keating D, Kermeen F, Kotlyar E, McWilliams T, Rhodes B, Steele P, Thakkar V, Williams T, Whitford H, Whyte K, Weintraub R, Wrobel JP, Keogh A, Strange G.

Chest. 2019 Sep 26. pii: S0012-3692(19)33934-0. doi: 10.1016/j.chest.2019.08.2203. [Epub ahead of print]

PMID:
31563497
2.

Rare cause of pulmonary hypertension - pulmonary tumour thrombotic microangiopathy.

O'Brien J, Jones N, Horrigan M, Al-Kaisey AM.

BMJ Case Rep. 2019 Aug 9;12(8). pii: e225756. doi: 10.1136/bcr-2018-225756.

PMID:
31401584
3.

The effect of surgery report cards on improving radical prostatectomy quality: the SuRep study protocol.

Breau RH, Kumar RM, Lavallee LT, Cagiannos I, Morash C, Horrigan M, Cnossen S, Mallick R, Stacey D, Fung-Kee-Fung M, Morash R, Smylie J, Witiuk K, Fergusson DA.

BMC Urol. 2018 Oct 19;18(1):89. doi: 10.1186/s12894-018-0403-y.

4.

Feasibility of using ultra-low pulse rate fluoroscopy during routine diagnostic coronary angiography.

Badawy MK, Scott M, Farouque O, Horrigan M, Clark DJ, Chan RK.

J Med Radiat Sci. 2018 Dec;65(4):252-258. doi: 10.1002/jmrs.293. Epub 2018 Jul 16.

5.

Improving Guideline Compliance in Australia With a National Percutaneous Coronary Intervention Outcomes Registry.

Eccleston D, Horrigan M, Rafter T, Holt G, Worthley SG, Sage P, Whelan A, Reid C, Thompson PL.

Heart Lung Circ. 2017 Dec;26(12):1303-1309. doi: 10.1016/j.hlc.2017.01.008. Epub 2017 Feb 28.

PMID:
28389196
6.

Development and external validation of a biopsy-derived nomogram to predict risk of ipsilateral extraprostatic extension.

Sayyid R, Perlis N, Ahmad A, Evans A, Toi A, Horrigan M, Finelli A, Zlotta A, Kulkarni G, Hamilton R, Morash C, Fleshner N.

BJU Int. 2017 Jul;120(1):76-82. doi: 10.1111/bju.13733. Epub 2017 Jan 6.

7.

The Receptor for Advanced Glycation End Products (RAGE) Is Associated with Persistent Atrial Fibrillation.

Lancefield TF, Patel SK, Freeman M, Velkoska E, Wai B, Srivastava PM, Horrigan M, Farouque O, Burrell LM.

PLoS One. 2016 Sep 14;11(9):e0161715. doi: 10.1371/journal.pone.0161715. eCollection 2016.

8.

Management of Patients Aged ≥85 Years With ST-Elevation Myocardial Infarction.

Yudi MB, Jones N, Fernando D, Clark DJ, Ramchand J, Jones E, Dakis R, Johnson D, Chan R, Islam A, Farouque O, Horrigan M.

Am J Cardiol. 2016 Jul 1;118(1):44-8. doi: 10.1016/j.amjcard.2016.04.010. Epub 2016 Apr 22.

PMID:
27217208
9.

Extended renal outcomes with use of iodixanol versus iohexol after coronary angiography.

Chua HR, Horrigan M, Mcintosh E, Bellomo R.

Biomed Res Int. 2014;2014:506479. doi: 10.1155/2014/506479. Epub 2014 Aug 7.

10.

Preventing surgical site infection: preoperative bathing, engaging patients and caregivers.

Froimson MI, Olivo K, Schill M, Horrigan MA.

Am J Orthop (Belle Mead NJ). 2013 Jun;42(6 Suppl):S5-8. Review. No abstract available.

PMID:
24911514
11.

Exploring the utility of high-resolution MS with post-acquisition data mining for simultaneous exogenous and endogenous metabolite profiling.

Barbara JE, Buckley DB, Horrigan MJ.

Bioanalysis. 2013 May;5(10):1211-28. doi: 10.4155/bio.13.102.

PMID:
23721444
12.

Long-term clinical outcomes with the next-generation Resolute Stent System: a report of the two-year follow-up from the RESOLUTE clinical trial.

Meredith IT, Worthley SG, Whitbourn R, Walters D, McClean D, Ormiston J, Horrigan M, Wilkins GT, Hendriks R, Matsis P, Muller D, Cutlip DE.

EuroIntervention. 2010 Jan;5(6):692-7.

PMID:
20142220
13.

Comparable patencies of the radial artery and right internal thoracic artery or saphenous vein beyond 5 years: results from the Radial Artery Patency and Clinical Outcomes trial.

Hayward PA, Gordon IR, Hare DL, Matalanis G, Horrigan ML, Rosalion A, Buxton BF.

J Thorac Cardiovasc Surg. 2010 Jan;139(1):60-5; discussion 65-7. doi: 10.1016/j.jtcvs.2009.09.043.

14.

Clinical and angiographic results with the next-generation resolute stent system: a prospective, multicenter, first-in-human trial.

Meredith IT, Worthley S, Whitbourn R, Walters DL, McClean D, Horrigan M, Popma JJ, Cutlip DE, DePaoli A, Negoita M, Fitzgerald PJ; RESOLUTE Investigators.

JACC Cardiovasc Interv. 2009 Oct;2(10):977-85. doi: 10.1016/j.jcin.2009.07.007.

15.

Advances in percutaneous treatment for adult valvular heart disease.

Wong MC, Clark DJ, Horrigan MC, Grube E, Matalanis G, Farouque HM.

Intern Med J. 2009 Jul;39(7):465-74. doi: 10.1111/j.1445-5994.2008.01877.x. Review.

PMID:
19664157
16.

Early- and long-term intravascular ultrasound and angiographic findings after bioabsorbable magnesium stent implantation in human coronary arteries.

Waksman R, Erbel R, Di Mario C, Bartunek J, de Bruyne B, Eberli FR, Erne P, Haude M, Horrigan M, Ilsley C, Böse D, Bonnier H, Koolen J, Lüscher TF, Weissman NJ; PROGRESS-AMS (Clinical Performance Angiographic Results of Coronary Stenting with Absorbable Metal Stents) Investigators.

JACC Cardiovasc Interv. 2009 Apr;2(4):312-20. doi: 10.1016/j.jcin.2008.09.015.

17.

Outcomes after percutaneous coronary intervention of ostial lesions in the era of drug-eluting stents.

Freeman M, Clark DJ, Andrianopoulos N, Duffy SJ, Lim HS, Brennan A, Charter K, Shaw J, Horrigan M, Ajani AE, Sebastian M, Reid CM, Farouque HM; Melbourne Interventional Group.

Catheter Cardiovasc Interv. 2009 May 1;73(6):763-8. doi: 10.1002/ccd.21941.

PMID:
19309731
18.

Treatment of unprotected left main disease with drug-eluting stents in patients at high risk for coronary artery bypass grafting.

Barlis P, Horrigan M, Elis S, Chan R, Wong M, Farouque O, Proimos G, Ajani AE, Clark DJ.

Cardiovasc Revasc Med. 2007 Apr-Jun;8(2):84-9.

PMID:
17574165
19.

Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial.

Erbel R, Di Mario C, Bartunek J, Bonnier J, de Bruyne B, Eberli FR, Erne P, Haude M, Heublein B, Horrigan M, Ilsley C, Böse D, Koolen J, Lüscher TF, Weissman N, Waksman R; PROGRESS-AMS (Clinical Performance and Angiographic Results of Coronary Stenting with Absorbable Metal Stents) Investigators.

Lancet. 2007 Jun 2;369(9576):1869-1875. doi: 10.1016/S0140-6736(07)60853-8.

PMID:
17544767
20.

Results of primary percutaneous coronary intervention in a consecutive group of patients with acute ST elevation myocardial infarction at a tertiary Australian centre.

van Gaal WJ, Clark D, Barlis P, Lim CC, Johns J, Horrigan M.

Intern Med J. 2007 Jul;37(7):464-71. Epub 2007 Apr 16.

PMID:
17445011
21.

Use of drug-eluting stents in Victorian public hospitals.

Yan BP, Ajani AE, Duffy SJ, New G, Horrigan M, Szto G, Walton A, Eccleston D, Lefkovits J, Black A, Sebastian M, Brennan AL, Reid CM, Clark DJ.

Med J Aust. 2006 Oct 2;185(7):363-7.

PMID:
17014403
22.

The foundation and launch of the Melbourne Interventional Group: a collaborative interventional cardiology project.

Ajani AE, Szto G, Duffy SJ, Eccleston D, Clark DJ, Lefkovits J, Chew DP, Warren R, Black A, New G, Walton A, Lew R, Shaw J, Horrigan M, Sebastian M, Yan BP, Brennan A, Meehan A, Reid C, Krum H; Melbourne Interventional Group investigators.

Heart Lung Circ. 2006 Feb;15(1):44-7. Epub 2005 Oct 27.

PMID:
16473790
23.

What is the best contemporary treatment for in-stent restenosis?

Barlis P, Horrigan MC, Chan RK, Ajani AE, Proimos G, Schumer W, van Gaal WJ, Rowe M, Eccleston D, Yan BB, Mun Cheong Y, Oliver LE, Clark DJ.

Cardiovasc Revasc Med. 2005 Oct-Dec;6(4):179-81.

PMID:
16326381
24.

Platypnea-orthodeoxia associated with a fenestrated atrial septal aneurysm: case report.

van Gaal WJ, Joseph M, Jones E, Matalanis G, Horrigan M.

Cardiovasc Ultrasound. 2005 Sep 13;3:28.

25.

The resistance of the IMA to atherosclerosis might be associated with its higher eNOS, ACE and ET-A receptor immunoreactivity.

Zulli A, Hare DL, Horrigan M, Buxton BF.

Arterioscler Thromb Vasc Biol. 2003 Jul 1;23(7):1308. No abstract available.

PMID:
12857717
26.

Radial artery patency and clinical outcomes: five-year interim results of a randomized trial.

Buxton BF, Raman JS, Ruengsakulrach P, Gordon I, Rosalion A, Bellomo R, Horrigan M, Hare DL.

J Thorac Cardiovasc Surg. 2003 Jun;125(6):1363-71.

27.

The Seldinger technique for insertion of difficult to place ventricular catheters.

Lam CH, Horrigan M, Lovick DS.

Pediatr Neurosurg. 2003 Feb;38(2):90-3.

PMID:
12566842
28.

Delayed neurally mediated syncope after inferior wall acute myocardial infarction.

O'Donnell D, Hamer A, Horrigan M.

Am J Cardiol. 2002 Jul 15;90(2):157-9. No abstract available.

PMID:
12106848
29.

Monte Carlo dosimetry of a tandem positioned beta-emitting intravascular brachytherapy source train.

Wallace SA, Schumer W, Horrigan M.

Med Phys. 2002 Apr;29(4):544-9.

PMID:
11991126
30.

Results of the study to determine rotablator and transluminal angioplasty strategy (STRATAS).

Whitlow PL, Bass TA, Kipperman RM, Sharaf BL, Ho KK, Cutlip DE, Zhang Y, Kuntz RE, Williams DO, Lasorda DM, Moses JW, Cowley MJ, Eccleston DS, Horrigan MC, Bersin RM, Ramee SR, Feldman T.

Am J Cardiol. 2001 Mar 15;87(6):699-705.

PMID:
11249886
31.

Reduction in myocardial infarct size by basic fibroblast growth factor following coronary occlusion in a canine model.

Horrigan MC, Malycky JL, Ellis SG, Topol EJ, Nicolini FA.

Int J Cardiol. 1999 Apr 10;68 Suppl 1:S85-91.

PMID:
10328616
32.

Left atrial tumour mimicking pulmonary embolism.

Seal EC, Rutter HR, Horrigan MC, Britton MG.

Respir Med. 1997 Oct;91(9):562-4.

33.

Myocardial Reperfusion Injury: From Bench to Bedside.

Horrigan MM, Nicolini FA.

J Thromb Thrombolysis. 1997 Jan;4(1):35-37. No abstract available.

PMID:
10639220
34.

Reduction in myocardial infarct size by basic fibroblast growth factor after temporary coronary occlusion in a canine model.

Horrigan MC, MacIsaac AI, Nicolini FA, Vince DG, Lee P, Ellis SG, Topol EJ.

Circulation. 1996 Oct 15;94(8):1927-33.

PMID:
8873670
35.
36.

Rationale for local drug delivery.

Eccleston DS, Horrigan MC, Ellis SG.

Semin Interv Cardiol. 1996 Mar;1(1):8-16. Review.

PMID:
9552480
37.

Direct angioplasty in acute myocardial infarction. State of the art and current controversies.

Horrigan MC, Topol EJ.

Cardiol Clin. 1995 Aug;13(3):321-38. Review.

PMID:
7585770
38.

Primary angioplasty for myocardial infarction.

Horrigan MC, Ellis SG.

J Invasive Cardiol. 1995;7 Suppl F:47F-62F. Review. No abstract available.

PMID:
10158395
39.

Dual chamber rate responsive pacing to allow sotalol therapy for ventricular tachycardia.

Horrigan MC, Davis MJ, May C, Smith P.

Pacing Clin Electrophysiol. 1992 Nov;15(11 Pt 2):2108-10.

PMID:
1279608

Supplemental Content

Loading ...
Support Center